Abstract:Abstract Background LRIG1, the founding member of the LRIG (leucine-rich repeat and immunoglobulin-like domain) family of transmembrane proteins, is a negative regulator of receptor tyrosine kinases and a tumour suppressor. Decreased LRIG1 expression is consistently observed in cancer, across diverse tumour types, and is linked to poor patient prognosis. However, mechanisms by which LRIG1 is repressed are not fully understood. Silencing of LRIG1 through promoter CpG island methylation has been reported in colorectal and cervical cancer but studies in breast cancer remain limited. Methods In silico analysis of human breast cancer patient data were used to demonstrate a correlation between DNA methylation and LRIG1 silencing in basal/triple-negative breast cancer, and its impact on patient survival. LRIG1 gene expression, protein abundance, and methylation enrichment were examined by quantitative reverse-transcription PCR, immunoblotting, and methylation immunoprecipitation, respectively, in breast cancer cell lines in vitro. We examined the impact of global demethylation on LRIG1 expression and methylation enrichment using 5-aza-2’-deoxycytidine. We also examined the effects of targeted demethylation of the LRIG1 CpG island, and transcriptional activation of LRIG1 expression, using the RNA guided deadCas9 transactivation system. Results Across breast cancer subtypes, LRIG1 expression is lowest in the basal/triple-negative subtype so we investigated whether differential methylation may contribute to this. Indeed, we find that LRIG1 CpG island methylation is most prominent in basal/triple-negative cell lines and patient samples. Use of the global demethylating agent 5-aza-2’-deoxycytidine decreases methylation leading to increased LRIG1 transcript expression in basal/triple-negative cell lines, while having no effect on LRIG1 expression in luminal/ER-positive cell lines. Using a CRISPR/deadCas9 (dCas9)-based targeting approach, we demonstrate that TET1-mediated demethylation (Tet1-dCas9) along with VP64-mediated transcriptional activation (VP64-dCas9) at the CpG island, increased endogenous LRIG1 expression in basal/triple-negative breast cancer cells, without transcriptional upregulation at predicted off-target sites. Activation of LRIG1 by the dCas9 transactivation system significantly increased LRIG1 protein abundance, reduced site-specific methylation, and reduced cancer cell viability. Our findings suggest that CRISPR-mediated targeted activation may be a feasible way to restore LRIG1 expression in cancer. Conclusions Our study contributes novel insight into mechanisms which repress LRIG1 in triple-negative breast cancer and demonstrates for the first time that targeted de-repression of LRIG1 in cancer cells is possible. Understanding the epigenetic mechanisms associated with repression of tumour suppressor genes holds potential for the advancement of therapeutic approaches.

LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.

Igfbp-Rp1, A Potential Molecule Associated with Colon Cancer Differentiation

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR

LRIG3 represses cell motility by inhibiting slug via inactivating ERK signaling in human colorectal cancer

LRG1 Promotes Proliferation and Inhibits Apoptosis in Colorectal Cancer Cells Via RUNX1 Activation.

A Role for LRIG1 in the Regulation of Malignant Glioma Aggressiveness.

Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer

Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity

LRG1 Modulates Epithelial-Mesenchymal Transition and Angiogenesis in Colorectal Cancer Via HIF-1α Activation

Epigenetic Silencing Oflrrc3bin Colorectal Cancer

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Polymeric Immunoglobulin Receptor Suppresses Colorectal Cancer Through the AKT-FOXO3/4 Axis by Downregulating LAMB3 Expression

LXRα-mediated downregulation of EGFR suppress colorectal cancer cell proliferation.

LRIG1 Enhances Chemosensitivity by Modulating BCL-2 Expression and Receptor Tyrosine Kinase Signaling in Glioma Cells.

Downregulation of LRRC19 Is Associated with Poor Prognosis in Colorectal Cancer

LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.

LRG1 Suppresses Migration and Invasion of Esophageal Squamous Cell Carcinoma by Modulating Epithelial to Mesenchymal Transition

Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is downregulated in Invasive ductal carcinoma and potential prognostic marker of breast cancer

LRIG 1-modulated invasion and metastasis of human gliomas through regulation of SNAI 2 and E-cadherin

LRIG1 regulates invasion and migration of human gliomas through SNAI2 and E-cadherin

Methylation of NRIP3 is a synthetic lethal marker for combined PI3K and ATR/ATM inhibitors in CRC